Alcobra Ltd

Alcobra: Does The Pre-Data Selloff Imply A Failed Phase 3? Roth Capital Comments

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Alcobra (NASDAQ:ADHD) with a $40 price target. The report comes …

Ben Mahaney, Editor — October 2, 2014, 3:25 PM EDT

Roth Capital Reiterates Buy On Alcobra Following The Completion Of Phase III Clinical Trial of MDX

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target of $40.00, …

Corey Williams — September 22, 2014, 12:36 PM EDT

Roth Capital Provides Input Into Alcobra’s Fragile X Program; Keeps $40 Price Target

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target …

Ben Mahaney, Editor — September 15, 2014, 1:25 PM EDT

Roth Capital Sees A Buy Opportunity In Alcobra Following Initiation Of Fragile X Phase 2b Study

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target …

Corey Williams — September 4, 2014, 11:08 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts